Migraine Management Essential 5: Abortive Treatment
This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The Migraine.com team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.
Interview: Teri Robert with John Claude Krusz, PhD, MD. February 26, 2011. • Ho, Dr. Tony W., MD; Ferrari, Prof. Michael D, MD; Dodick, Prof. David W., MD; Galet, Vince, PhD; Kost, James, PhD; Fan, Xiaoyn, PhD; Leibensperger, Heather, BS; Froman, Samar, BS, Assaid, Christopher, PhD; Oines, Christopher, PhD; Koppen, Hille, MD; Winner, Paul K., DO. "Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial." The Lancet, Early Online Publication. November 25, 2008. • Robert, Teri. “Living Well with Migraine Disease and Headaches.” New York. HarperCollins. 2005. • Cohen, Anna S., PhD, MRCP; Burns, Brian, MD, MRCP; Goadsby, Peter J. MD, PhD, DSc, FRACP, FRCP. "Hight-Flow Oxygen for Treatment of Cluster Headache." JAMA, December 9, 2009—Vol 302, No. 22. • Interview: Teri Robert with Tony Ho., M.D., senior director of Clinical Neurosciences, Merck Research Laboratories. June 7, 2007.